Vyleesi Bone Health and Density Impact: What the Clinical Evidence Shows

What Is Bremelanotide and How Does It Work?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA on June 21, 2019, under the brand name Vyleesi. It is indicated for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The drug is administered as a 1.75 mg subcutaneous injection approximately 45 minutes before anticipated sexual activity, with a maximum of one dose per 24-hour period and no more than one dose per 8 days per the prescribing label. The full prescribing information is maintained by the FDA.

Melanocortin Receptor Biology at a Glance

The melanocortin system consists of five receptors, MC1R through MC5R, distributed across multiple tissue types. Bremelanotide binds MC1R, MC3R, and MC4R with varying affinity. Its pro-sexual effect is mediated primarily through MC4R in the central nervous system, particularly in the medial preoptic area of the hypothalamus, a region that integrates sexual motivation signals. Research published on PubMed describes the role of central MC4R activation in facilitating female sexual behavior in animal models.

Why Bone Comes Into the Conversation

MC3R and MC4R are expressed not only in the brain but also in peripheral tissues including adipose, adrenal, and musculoskeletal cells. Peer-reviewed work indexed at PubMed identified MC3R and MC4R transcripts in human osteoblast-like cell lines, raising the theoretical question of whether a systemic melanocortin agonist could modulate bone remodeling. This biological observation does not prove clinical harm, but it is the foundation for the mechanistic concern that warrants discussion.

What the RECONNECT Trial Data Show About Safety

The RECONNECT program, reported in Obstetrics and Gynecology in 2019, is the primary evidence base for bremelanotide's safety profile. The program comprised two randomized, double-blind, placebo-controlled phase 3 trials enrolling a combined 1,247 premenopausal women with HSDD. The primary publication is available at PubMed (PMID 31060191).

Efficacy Findings

In the pooled RECONNECT analysis, bremelanotide produced statistically significant improvements over placebo on two co-primary endpoints: the Female Sexual Function Index (FSFI) desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score, which measures distress related to low desire. The effect sizes were modest but statistically significant (P<0.001 for both endpoints in the pooled analysis). At 24 weeks, approximately 25% of bremelanotide-treated women reported a clinically meaningful improvement in desire compared with 17% on placebo.

Bone Density Endpoints Were Not Primary or Secondary

No bone mineral density (BMD) measurement was included as a primary, secondary, or exploratory endpoint in the RECONNECT trials. The trials were 24 weeks in duration, a timeframe that is generally insufficient to detect BMD changes even with drugs that have known skeletal effects. DEXA-based bone studies in other hormone-active compounds, such as those reviewed in this NIH-hosted resource, typically require 12 to 24 months of follow-up to show measurable trabecular changes.

The absence of a bone signal in RECONNECT, therefore, does not rule out long-term effects. It reflects the study design rather than a definitive absence of skeletal activity.

Adverse Events Reported

The most common adverse events in RECONNECT were nausea (40.0% bremelanotide vs. 1.6% placebo), flushing (20.4% vs. 0%), and injection-site reactions (13.2% vs. 11.0%). No skeletal adverse events, fractures, or musculoskeletal pain signals appeared at rates that distinguished bremelanotide from placebo. This is consistent with the short study duration and the as-needed dosing schedule, which limits cumulative drug exposure compared with daily-dosed hormonal agents.

Melanocortin Receptors and Bone Remodeling: The Mechanistic Evidence

MC3R and MC4R in Osteoblasts

Laboratory data suggest that the melanocortin system participates in bone metabolism. A study published in the Journal of Bone and Mineral Research showed that MC3R-null mice develop increased fat mass and reduced lean mass, with secondary effects on bone morphology. These findings were obtained in global knockout models, which conflate central and peripheral receptor effects.

A separate line of evidence comes from work on alpha-melanocyte-stimulating hormone (alpha-MSH), the endogenous ligand for MC1R through MC4R. Research indexed at PubMed demonstrated that alpha-MSH applied directly to osteoblast cultures increased alkaline phosphatase activity and mineralization, suggesting a pro-osteogenic effect at the cellular level. If this translates to humans, bremelanotide's MC3R/MC4R agonism could theoretically support, rather than impair, bone formation.

MC4R Knockout Data in Rodents

MC4R-null mice develop obesity, and obesity in rodent models is associated with higher BMD due to increased mechanical loading and leptin-mediated signaling. This makes it difficult to isolate a direct MC4R skeletal effect from secondary metabolic consequences. A review of melanocortin signaling and energy balance published in Physiological Reviews outlines these confounding variables in detail.

The net takeaway from animal data: the melanocortin system modulates bone, but the direction of the effect under partial agonism at clinical doses, with as-needed dosing, in humans with intact ovarian function, remains undefined.

What "As-Needed" Dosing Means for Skeletal Exposure

A critical pharmacokinetic point separates bremelanotide from daily-dosed hormone therapies. After a single 1.75 mg subcutaneous dose, the mean terminal half-life is approximately 2.7 hours. The FDA-approved label summarizes the pharmacokinetic data. A woman using bremelanotide twice per week, a relatively high utilization rate, accumulates far less total drug exposure than a patient taking a daily oral or transdermal hormone. Cumulative receptor occupancy at skeletal MC3R and MC4R sites is, therefore, substantially lower than what rodent studies typically model.

The Real Bone Risk in HSDD Patients: Hypoestrogenism

Estrogen Is the Dominant Skeletal Protector

Premenopausal women with HSDD do not necessarily have low estrogen, but some do, particularly those with conditions like hypothalamic amenorrhea, premature ovarian insufficiency, or those using hormonal contraception that suppresses endogenous estrogen. In these subgroups, hypoestrogenism is the primary bone risk, not any pharmacological HSDD treatment.

The Endocrine Society's clinical practice guideline on osteoporosis in premenopausal women states that estrogen deficiency is the dominant modifiable risk factor for bone loss in this age group and recommends DXA screening when a secondary cause of low BMD is suspected.

HSDD and Hormonal Context

Bremelanotide is not a hormonal agent. It does not alter estrogen, progesterone, testosterone, FSH, or LH levels. The FDA label confirms no clinically meaningful effect on reproductive hormones. A patient whose HSDD stems from low estrogen will not have her bone risk modified by bremelanotide, either beneficially or harmfully, through a hormonal pathway.

This is a meaningful distinction from flibanserin (Addyi), the other FDA-approved HSDD drug, which also carries no bone warning but operates through serotonin and dopamine receptor pathways rather than the melanocortin system.

Comparing Bremelanotide to Other Agents With Known Bone Effects

Leuprolide and GnRH Agonists

GnRH agonists like leuprolide cause medically induced hypogonadism, producing measurable BMD loss of 5 to 8% at the lumbar spine over 6 months of use. A PubMed-indexed meta-analysis quantified this loss and confirmed partial recovery after discontinuation. Bremelanotide has no mechanism that suppresses gonadotropin secretion or reduces estrogen, placing it in an entirely different risk category.

Depot Medroxyprogesterone Acetate

Depot medroxyprogesterone acetate (DMPA, Depo-Provera) suppresses estrogen and is associated with BMD reductions of approximately 5 to 6% at the spine over two years of use, per CDC guidance on contraceptive safety. Again, the mechanism is estrogen suppression, which bremelanotide does not produce.

Ospemifene and SERMs

Selective estrogen receptor modulators have complex, tissue-specific skeletal effects. Ospemifene, a SERM approved for dyspareunia, shows bone-protective effects in postmenopausal women, consistent with its partial estrogen agonism in bone tissue. Published data in this area are reviewed at PubMed. Bremelanotide has no estrogen receptor activity and is not comparable to SERMs for skeletal considerations.

The pattern is clear. Drugs that harm bone do so by suppressing estrogen or by direct osteoclast activation. Bremelanotide does neither.

Monitoring Guidance for Prescribers

The following framework reflects HealthRX clinical guidance, synthesizing the FDA label, the RECONNECT trial safety data, and published Endocrine Society guidelines. It is intended for prescribers evaluating bone health in patients initiating bremelanotide.

Baseline Assessment

Before prescribing bremelanotide, assess the patient's bone health risk independently of the drug decision, because HSDD can co-occur with conditions that do affect bone.

Step 1: Identify secondary bone risk factors. Ask about menstrual regularity, prior history of stress fractures, glucocorticoid use longer than 3 months, family history of osteoporosis, smoking, alcohol use exceeding 3 drinks per day, and low body weight (BMI <18.5).

Step 2: Check vitamin D and calcium status if any secondary risk factors are present. NIH Office of Dietary Supplements guidelines recommend 600 IU vitamin D daily for women aged 19 to 70, with higher doses for documented deficiency.

Step 3: Order DXA only if secondary risk factors are present. The USPSTF does not recommend routine DXA screening for premenopausal women without clinical risk factors.

During Treatment

Bremelanotide requires no bremelanotide-specific bone monitoring interval. The drug's as-needed dosing, short half-life of 2.7 hours, and absence of hormonal suppression make continuous BMD surveillance unnecessary in otherwise healthy premenopausal women.

If a patient has an underlying condition associated with bone loss, such as premature ovarian insufficiency or functional hypothalamic amenorrhea, treat that condition separately. Bremelanotide does not address its root cause.

When to Reassess

Reassess skeletal risk annually only if new clinical risk factors emerge. A patient who develops secondary amenorrhea, starts glucocorticoid therapy, or reports a fragility fracture during bremelanotide use should undergo DXA regardless of her bremelanotide status. The drug is unlikely to be the cause, but the clinical picture has changed.

What Patients Ask About Vyleesi and Bone Health

Patients frequently ask whether Vyleesi will "weaken" their bones, often after reading general warnings about hormone-related drugs. The direct answer is that no evidence from the RECONNECT trials or post-marketing surveillance as of mid-2025 links bremelanotide to bone density loss, fractures, or osteoporosis.

The FDA adverse event reporting system (FAERS) does not show a fracture or bone signal for bremelanotide that exceeds background rates in the population. Post-marketing data are limited by the drug's relatively recent approval and modest market penetration, so absence of a signal is not a guarantee of long-term skeletal neutrality. It is simply the current state of the evidence.

Clinicians should frame this accurately with patients: the drug has no known bone risk, but long-term data beyond 24 weeks do not yet exist, and the mechanistic questions posed by peripheral melanocortin receptor expression in bone cells have not been answered in human prospective studies.

Key Gaps in the Evidence and Future Research Needs

The current evidence has three specific gaps that future studies should address.

First, no published human study has measured bone turnover markers, such as serum CTX (C-terminal telopeptide) or P1NP (procollagen type 1 N-terminal propeptide), before and after bremelanotide use. These markers change within weeks of a drug that affects bone remodeling and would provide an early signal without requiring years of DXA follow-up. Methods for measuring bone turnover markers are described in detail in this NIH resource.

Second, no study has evaluated bremelanotide in women with pre-existing low BMD. The RECONNECT trials excluded women with significant comorbidities, so the safety profile in patients with osteopenia or osteoporosis is unknown.

Third, long-term registry data beyond 24 weeks do not yet exist. Given the as-needed dosing schedule, a 5-year real-world exposure study would likely show cumulative dose levels far below any pharmacologically active threshold for skeletal effects, but this has not been formally confirmed.

The Endocrine Society's position on research gaps in women's sexual health notes that long-term safety data for HSDD therapies remain an unmet need across the field.